patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_457108 | REC_0007701 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 6.1 | 82 | female | 2 | 17 | 4.8 | 7 | entrectinib 600 mg daily | 9 | true | MSS | 2026-03-15T05:35:58.742177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996834 | REC_0007702 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.3 | 74 | female | 2 | 22 | 5.5 | 5 | sotorasib 960 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.742407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306801 | REC_0007703 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.7 | 78 | female | 2 | 14 | 6.5 | 2 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.742647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958349 | REC_0007704 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.3 | 74 | male | 3 | 22 | 5.4 | 7 | pembrolizumab 200 mg q3w | 10 | false | MSI-H | 2026-03-15T05:35:58.742887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946725 | REC_0007705 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 9.3 | 64 | male | 0 | 27 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.743127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590854 | REC_0007706 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 14.5 | 74 | female | 1 | 11 | 4.7 | 2 | osimertinib 80 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:35:58.743366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753707 | REC_0007707 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 10.9 | 75 | female | 0 | 22 | 5.5 | 5 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:58.743598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707455 | REC_0007708 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6.2 | 73 | female | 2 | 23 | 3.8 | 2 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:58.743830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975753 | REC_0007709 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 5.5 | 74 | male | 1 | 10 | 6.1 | 7 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:58.744064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773478 | REC_0007710 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 7.2 | 78 | female | 2 | 24 | 5.3 | 2 | alectinib 600 mg BID | 6.9 | true | MSS | 2026-03-15T05:35:58.744451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105215 | REC_0007711 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.1 | 73 | female | 2 | 17 | 4.6 | 6 | osimertinib 80 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.744692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444199 | REC_0007712 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.4 | 77 | female | 2 | 9 | 7.3 | 5 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.744923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784127 | REC_0007713 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.4 | 65 | male | 0 | 17 | 5.4 | 8 | entrectinib 600 mg daily | 5.4 | true | MSS | 2026-03-15T05:35:58.745159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523187 | REC_0007714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 9.4 | 70 | female | 3 | 16 | 3.3 | 5 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:35:58.745391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417373 | REC_0007715 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13 | 71 | male | 1 | 6 | 4.2 | 1 | sotorasib 960 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:58.745630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221829 | REC_0007716 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.9 | 67 | female | 0 | 10 | 5.7 | 8 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.745857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916266 | REC_0007717 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.2 | 62 | male | 1 | 19 | 5.3 | 6 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:58.746091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296670 | REC_0007718 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 3.5 | 69 | female | 0 | 15 | 5 | 5 | alectinib 600 mg BID | 16.7 | false | MSS | 2026-03-15T05:35:58.746321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278297 | REC_0007719 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 9 | 58 | male | 1 | 31 | 5.5 | 7 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:58.746553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232960 | REC_0007720 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 13 | 75 | female | 0 | 20 | 6.2 | 1 | entrectinib 600 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:58.746786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858820 | REC_0007721 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.2 | 78 | female | 2 | 15 | 5.3 | 5 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:58.747014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626778 | REC_0007722 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 10.2 | 60 | female | 0 | 5 | 6.8 | 2 | sotorasib 960 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:58.747249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214869 | REC_0007723 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 4.7 | 74 | female | 1 | 21 | 4.3 | 6 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:58.747527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513830 | REC_0007724 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 7.7 | 65 | female | 0 | 21 | 5.2 | 1 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:58.747764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639046 | REC_0007725 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.6 | 74 | female | 0 | 16 | 6.1 | 1 | entrectinib 600 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:35:58.747998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158486 | REC_0007726 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.3 | 70 | male | 1 | 16 | 4.8 | 6 | sotorasib 960 mg daily | 7 | true | MSS | 2026-03-15T05:35:58.748298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597216 | REC_0007727 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 7.9 | 61 | female | 1 | 13 | 4.8 | 1 | osimertinib 80 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:58.748543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138289 | REC_0007728 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 10.2 | 77 | female | 1 | 16 | 4.8 | 2 | osimertinib 80 mg daily | 24.6 | true | MSS | 2026-03-15T05:35:58.748779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424662 | REC_0007729 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.7 | 70 | female | 2 | 17 | 3.2 | 2 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:58.749013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330022 | REC_0007730 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.6 | 62 | female | 0 | 14 | 3.9 | 6 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:35:58.749248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314837 | REC_0007731 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 36 | 6 | 46 | female | 0 | 43 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:35:58.749480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678348 | REC_0007732 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.7 | 66 | female | 0 | 21 | 5.2 | 6 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.749711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659743 | REC_0007733 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 19.3 | 63 | female | 1 | 10 | 5 | 2 | osimertinib 80 mg daily | 22.6 | true | MSI-H | 2026-03-15T05:35:58.749945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939571 | REC_0007734 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 13.3 | 48 | female | 0 | 14 | 4.5 | 1 | alectinib 600 mg BID | 23.1 | false | MSI-H | 2026-03-15T05:35:58.750178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935645 | REC_0007735 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 8.6 | 63 | female | 1 | 22 | 6.6 | 2 | pembrolizumab 200 mg q3w | 21.2 | true | MSS | 2026-03-15T05:35:58.750411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989987 | REC_0007736 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 29 | 14 | 76 | female | 1 | 13 | 5.1 | 0 | sotorasib 960 mg daily | 39.5 | false | MSI-H | 2026-03-15T05:35:58.750686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927170 | REC_0007737 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 18.5 | 73 | female | 1 | 28 | 7.1 | 1 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:35:58.750943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165638 | REC_0007738 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.4 | 56 | male | 0 | 12 | 5 | 5 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:58.751251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606408 | REC_0007739 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 13.4 | 61 | female | 0 | 13 | 4.7 | 6 | sotorasib 960 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:58.751532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373661 | REC_0007740 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 12.2 | 62 | male | 1 | 13 | 6.2 | 7 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:58.751791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307592 | REC_0007741 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.5 | 71 | male | 1 | 15 | 6.1 | 5 | sotorasib 960 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:35:58.752041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697941 | REC_0007742 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.1 | 72 | male | 2 | 9 | 5.3 | 2 | alectinib 600 mg BID | 19 | false | MSS | 2026-03-15T05:35:58.752328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820726 | REC_0007743 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 8.6 | 78 | female | 1 | 26 | 7.5 | 5 | sotorasib 960 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:58.752574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389560 | REC_0007744 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 10.6 | 69 | female | 1 | 14 | 6.7 | 2 | pembrolizumab 200 mg q3w | 24.4 | false | MSS | 2026-03-15T05:35:58.752820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661167 | REC_0007745 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 18.2 | 56 | female | 1 | 13 | 6.1 | 2 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.753067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880963 | REC_0007746 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.8 | 65 | female | 1 | 16 | 3.9 | 6 | sotorasib 960 mg daily | 4.4 | true | MSI-H | 2026-03-15T05:35:58.753312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272057 | REC_0007747 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.6 | 54 | male | 0 | 18 | 6.1 | 4 | alectinib 600 mg BID | 15.9 | false | MSI-H | 2026-03-15T05:35:58.753559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719466 | REC_0007748 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.8 | 72 | male | 1 | 20 | 4.6 | 1 | entrectinib 600 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:58.753809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367627 | REC_0007749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 49 | female | 0 | 50 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:58.754147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138160 | REC_0007750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 11.2 | 71 | female | 1 | 18 | 3.6 | 5 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.754397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651083 | REC_0007751 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.4 | 46 | male | 0 | 0 | 7 | 7 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:58.754632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865961 | REC_0007752 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13 | 69 | female | 1 | 13 | 5.1 | 5 | sotorasib 960 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:58.754871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987007 | REC_0007753 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14.2 | 60 | female | 1 | 25 | 5.3 | 2 | alectinib 600 mg BID | 30.9 | true | MSS | 2026-03-15T05:35:58.755118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848534 | REC_0007754 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.4 | 74 | male | 1 | 15 | 3.6 | 6 | entrectinib 600 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:58.755371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482447 | REC_0007755 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 5.7 | 62 | male | 0 | 14 | 6.3 | 6 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:58.755620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378504 | REC_0007756 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 16.5 | 68 | male | 0 | 13 | 6.8 | 2 | sotorasib 960 mg daily | 20.7 | true | MSI-H | 2026-03-15T05:35:58.755872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821906 | REC_0007757 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 17.7 | 61 | female | 0 | 15 | 6.2 | 2 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.756175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760088 | REC_0007758 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 8.8 | 67 | female | 0 | 27 | 4.6 | 1 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.756427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102117 | REC_0007759 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.5 | 68 | female | 0 | 31 | 3.7 | 5 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:35:58.756681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159753 | REC_0007760 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.7 | 70 | female | 0 | 30 | 5.5 | 2 | pembrolizumab 200 mg q3w | 14.9 | true | MSS | 2026-03-15T05:35:58.756921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373136 | REC_0007761 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.2 | 63 | female | 0 | 12 | 5.7 | 4 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:58.757166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834662 | REC_0007762 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.8 | 66 | female | 1 | 23 | 4.4 | 3 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.757505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693324 | REC_0007763 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.3 | 71 | female | 2 | 22 | 5.5 | 6 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.757764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396488 | REC_0007764 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 13.3 | 66 | female | 0 | 7 | 6.9 | 6 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:35:58.758009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772047 | REC_0007765 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 20.6 | 82 | female | 2 | 22 | 5.2 | 2 | sotorasib 960 mg daily | 22.9 | false | MSI-H | 2026-03-15T05:35:58.758262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123922 | REC_0007766 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.8 | 67 | female | 0 | 22 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:58.758508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557345 | REC_0007767 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 10.8 | 72 | female | 1 | 19 | 4.4 | 2 | alectinib 600 mg BID | 11.1 | false | MSI-H | 2026-03-15T05:35:58.758766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930822 | REC_0007768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.7 | 68 | male | 1 | 16 | 4.2 | 5 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:58.759023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438473 | REC_0007769 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.1 | 68 | female | 0 | 14 | 2.9 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.759267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207006 | REC_0007770 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.7 | 69 | female | 0 | 15 | 5.3 | 3 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.759518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771304 | REC_0007771 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.8 | 78 | male | 1 | 20 | 4 | 6 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.759765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906156 | REC_0007772 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.4 | 64 | male | 0 | 61 | 7.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.760011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662144 | REC_0007773 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.5 | 70 | female | 1 | 18 | 5.2 | 1 | entrectinib 600 mg daily | 6.7 | true | MSI-H | 2026-03-15T05:35:58.760372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167617 | REC_0007774 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.5 | 72 | female | 2 | 17 | 5.1 | 1 | osimertinib 80 mg daily | 16.5 | true | MSI-H | 2026-03-15T05:35:58.760626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559049 | REC_0007775 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 7.1 | 64 | male | 1 | 10 | 4.7 | 8 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.760987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109875 | REC_0007776 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.9 | 54 | female | 0 | 20 | 6.2 | 6 | alectinib 600 mg BID | 6.1 | false | MSI-H | 2026-03-15T05:35:58.761241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794659 | REC_0007777 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.8 | 85 | female | 3 | 23 | 3.2 | 2 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:58.761490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121387 | REC_0007778 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 74 | female | 1 | 9 | 4.2 | 7 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.761738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646973 | REC_0007779 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.5 | 60 | male | 1 | 14 | 3.8 | 5 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.761996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177340 | REC_0007780 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 20 | 8.4 | 81 | female | 2 | 17 | 7.6 | 0 | osimertinib 80 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:58.762243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247133 | REC_0007781 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 16.8 | 64 | female | 0 | 12 | 6.2 | 4 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:58.762494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484230 | REC_0007782 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 6.5 | 68 | female | 1 | 50 | 3.8 | 1 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:35:58.762732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220764 | REC_0007783 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 15 | 7.2 | 81 | female | 1 | 62 | 5.5 | 3 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:58.762983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462548 | REC_0007784 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.8 | 73 | female | 1 | 51 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:58.763230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567829 | REC_0007785 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 6.3 | 52 | female | 0 | 13 | 6.7 | 6 | entrectinib 600 mg daily | 8 | true | MSS | 2026-03-15T05:35:58.763481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806568 | REC_0007786 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 15 | 59 | female | 0 | 12 | 3.4 | 5 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.763737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807641 | REC_0007787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 5 | 71 | female | 0 | 28 | 7 | 6 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:35:58.763981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225781 | REC_0007788 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 6.3 | 73 | female | 1 | 17 | 4.7 | 1 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:58.764391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715938 | REC_0007789 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.4 | 65 | male | 0 | 44 | 4.9 | 2 | pembrolizumab 200 mg q3w | 25.2 | false | MSS | 2026-03-15T05:35:58.764657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877165 | REC_0007790 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.6 | 74 | male | 1 | 13 | 3.7 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.764913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524847 | REC_0007791 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.6 | 65 | female | 0 | 14 | 5.3 | 2 | entrectinib 600 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:58.765168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892542 | REC_0007792 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 20.2 | 58 | female | 1 | 9 | 4.7 | 5 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.765423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522149 | REC_0007793 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 6.3 | 64 | male | 1 | 64 | 4.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 28.2 | false | MSS | 2026-03-15T05:35:58.765674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785447 | REC_0007794 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 7.6 | 64 | female | 0 | 14 | 4.5 | 1 | osimertinib 80 mg daily | 20.2 | true | MSS | 2026-03-15T05:35:58.765927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232805 | REC_0007795 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.1 | 75 | female | 1 | 10 | 6.2 | 5 | entrectinib 600 mg daily | 17 | true | MSS | 2026-03-15T05:35:58.766173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147271 | REC_0007796 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12 | 74 | male | 1 | 1 | 5.6 | 5 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:58.766424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814744 | REC_0007797 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 6.8 | 69 | male | 1 | 7 | 5 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.766670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793924 | REC_0007798 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 11.2 | 66 | male | 0 | 44 | 8.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSI-H | 2026-03-15T05:35:58.766922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576709 | REC_0007799 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 15 | 15.3 | 66 | female | 1 | 15 | 5.4 | 6 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:58.767177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358209 | REC_0007800 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 14 | 69 | female | 0 | 11 | 8.4 | 2 | sotorasib 960 mg daily | 26.1 | false | MSS | 2026-03-15T05:35:58.767423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.